EMEA-002599-PIP01-19-M01
Key facts
| Active substance |
Zoliflodacin
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0381/2022
|
| PIP number |
EMEA-002599-PIP01-19-M01
|
| Pharmaceutical form(s) |
Granules for oral suspension
|
| Condition(s) / indication(s) |
Treatment of gonococcal infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Entasis Therapeutic Inc.
E-mail: Enquiries@entasistx.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|